Adaptive Biotechnologies 주식 (NASDAQ: ADPT)

에 대한 최신 뉴스 Adaptive Biotechnologies (NASDAQ:ADPT) 주식

Adaptive Biotechnologies

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Adeptus Health

Equities

News

Markets

ETFs

ADPT

ARKF

ARKG

ARKK

BEAM

MELI

금요일에 캐시 우드가 이끄는 안크 인베스트가 빔 테라퓨틱스(NASDAQ:BEAM), 누 홀딩스(NYSE:NU), 메르카도리브레(NASDAQ:MELI), 그리고 어댑티브 바이오테크놀로지스(NASDAQ:ADPT)와 관련하여 큰 거래를 했다.

아크 인베스트, 빔 테라퓨틱스와 누 홀딩스에 투자 확대: 메르카도리브레와 어댑티브 매도

Tech

CDNA

PLTR

VCYT

월요일(13일) 캐시 우드가 이끄는 아크 인베스트는 팔란티어 테크놀로지스(NASDAQ:PLTR), 템퍼스 AI(NASDAQ:TEM), 케어Dx (NASDAQ:CDNA), 베라사이트(NASDAQ:VCYT), 어댑티브 바이오테크놀로지스 (NASDAQ:ADPT) 등 5개의 주요 기업에서 중요한 거래를 진행했다.

캐시 우드의 아크 인베스트, 팔란티어 주가 하락 속 추가 매도

ILMN

NTLA

RXRX

캐시 우드가 이끄는 아크 인베스트는 금요일에 리커젼 파마슈티컬스(NASDAQ:RXRX), 일루미나(NASDAQ:ILMN), 인텔리아 테라퓨틱스(NASDAQ:NTLA), 클라우드플레어(NYSE:NET) 그리고 어댑티브 바이오테크놀로지스(NASDAQ:ADPT)의 주요 회사들에서 상당한 거래를 진행했다.

캐시 우드의 아크 인베스트, 인력의 4분의 1 이상을 해고한 인텔리아 테라퓨틱스에 투자

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

On Friday, Cathie Wood-led Ark Invest made significant trades involving Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>), MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), and Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The BEAM Trade
Ark Invest, through its ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), bought a total of 24,640 shares of Beam Therapeutics.
This comes after the firm&#8217;s <a href="https://www.benzinga.com/25/02/43755344/cathie-woods-ark-invest-loads-up-on-iridium-twist-bioscience-offloads-roku-here-are-key-ark-trades-this-friday">previous acquisition</a> of Beam Therapeutics shares just a week prior. The value of this trade, calculated from the latest closing price is nearly $750,000.
The NU Trade
Ark Invest, through its ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark&#8217;s strategic positioning in the dynamic tech sector.
The value of this trade, calculated from the latest closing price is over $1.75 million.
The MELI and ADPT Trades
On the same day, Ark Invest also sold shares of MercadoLibre Inc and Adaptive Biotechnologies Corp. Through its ARK Fintech Innovation ETF, Ark sold 347 shares of MercadoLibre.
Meanwhile, through its ARK Genomic Revolution ETF, Ark offloaded 8,129 shares of Adaptive Biotechnologies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43900360/bill-gates-has-a-warning-for-the-next-generation-says-be-very-afraid-of-these-4-issues">Bill Gates Has A Warning For The Next Generation, Says Be ‘Very Afraid&#8217; Of These 4 Issues</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Ark Invest

Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies

Piper Sandler analyst David Westenberg reiterates Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Overweight and raises the price target from $7 to $11.

Price Target

Reiteration

Analyst Ratings

Piper Sandler Reiterates Overweight on Adaptive Biotechnologies, Raises Price Target to $11

Scotiabank analyst Sung Ji Nam maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Sector Outperform and raises the price target from $10 to $12.

Scotiabank Maintains Sector Outperform on Adaptive Biotechnologies, Raises Price Target to $12

WIIM

Adaptive Biotechnologies shares are trading lower. The company reported Q4 financial results.

Guidance

Adaptive Biotechnologies Sees FY25 Revenue For MRD Business $175M-$185M

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.26) by 11.54 percent. The company reported quarterly sales of $47.459 million which beat the analyst consensus estimate of $46.034 million by 3.09 percent. This is a 3.66 percent increase over sales of $45.784 million the same period last year.

Earnings

Earnings Beats

Adaptive Biotechnologies Q4 2024 GAAP EPS $(0.23) Beats $(0.26) Estimate, Sales $47.459M Beat $46.034M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) is estimated to report quarterly earnings at $1.05 per share on revenue of $743.60 million. 
• AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) is likely to report quarterly earnings at $4.26 per share on revenue of $6.81 billion. 
• Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) is estimated to report quarterly loss at $2.12 per share on revenue of $28.84 billion. 
• Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $5.20 billion. 
• DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is projected to report quarterly earnings at $0.98 per share on revenue of $3.07 billion. 
• BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $45.65 billion. 
• Yatra Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTRA#NASDAQ">YTRA</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $15.02 million. 
• NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $217.60 million. 
• OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $48.93 million. 
• Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) is estimated to report quarterly loss at $1.04 per share on revenue of $59.49 million. 
• Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) is expected to report quarterly loss at $0.01 per share on revenue of $26.52 million. 
• Jerash Holdings (US) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRSH#NASDAQ">JRSH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $37.65 million. 
• Ceragon Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $105.16 million. 
• SolarWinds (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $202.91 million. 
• Curbline Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURB#NYSE">CURB</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $28.88 million. 
• IPG Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $229.47 million. 
• LCI Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $799.81 million. 
• Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) is likely to report quarterly loss at $0.07 per share on revenue of $10.50 million. 
• Sunoco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) is likely to report quarterly earnings at $1.34 per share on revenue of $5.92 billion. 
• WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $650.00 million. 
• Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $2.63 billion. 
• Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) is likely to report quarterly earnings at $2.36 per share on revenue of $6.39 billion. 
• MYT Netherlands Parent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $217.77 million. 
• Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $2.73 billion. 
• WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) is expected to report quarterly earnings at $3.23 per share on revenue of $5.42 billion. 
• TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $463.18 million. 
• USA Compression Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $242.95 million. 
• S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) is projected to report quarterly earnings at $3.41 per share on revenue of $3.46 billion. 
• Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $10.70 billion. 
• Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) is projected to report quarterly earnings at $2.27 per share on revenue of $4.13 billion. 
• Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $1.84 billion. 
• GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $1.83 billion. 
• Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) is expected to report quarterly earnings at $1.81 per share on revenue of $4.03 billion. 
<h3>Companies Reporting After The Bell</h3>
• Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is likely to report quarterly earnings at $1.70 per share on revenue of $7.15 billion. 
• Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) is projected to report quarterly earnings at $1.06 per share on revenue of $129.03 million. 
• Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) is projected to report quarterly loss at $1.03 per share on revenue of $2.73 billion. 
• Franklin Street Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSP#AMEX">FSP</a>) is projected to report quarterly loss at $0.07 per share on revenue of $30.83 million. 
• Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is projected to report quarterly earnings at $0.55 per share on revenue of $1.49 billion. 
• Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $5.78 billion. 
• Evolution Petroleum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EPM#AMEX">EPM</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $22.73 million. 
• Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $144.62 million. 
• Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) is projected to report quarterly loss at $0.16 per share on revenue of $6.59 million. 
• Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) is expected to report earnings for its fourth quarter. 
• United Fire Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFCS#NASDAQ">UFCS</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $327.70 million. 
• Tigo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $15.62 million. 
• HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $28.48 million. 
• Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) is likely to report quarterly loss at $0.14 per share on revenue of $500 thousand. 
• Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) is projected to report quarterly loss at $1.38 per share on revenue of $14.11 million. 
• Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $562.72 million. 
• Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $106.25 million. 
• BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $168.10 million. 
• Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) is likely to report quarterly earnings at $4.90 per share on revenue of $766.63 million. 
• Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) is likely to report quarterly earnings at $1.91 per share on revenue of $765.40 million. 
• Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $15.30 million. 
• W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) is estimated to report quarterly earnings at $1.20 per share on revenue of $397.32 million. 
• Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $883.43 million. 
• Pitney Bowes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $509.65 million. 
• America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $12.27 billion. 
• Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $3.13 billion. 
• Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) is expected to report quarterly loss at $0.24 per share on revenue of $45.84 million. 
• Anterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>) is expected to report quarterly loss at $0.61 per share on revenue of $1.88 million. 
• IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $934.31 million. 
• Mercury General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) is estimated to report quarterly earnings at $0.64 per share on revenue of $1.23 billion. 
• American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) is expected to report quarterly earnings at $1.53 per share on revenue of $6.70 billion. 
• Diodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $337.10 million. 
• Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) is projected to report quarterly loss at $0.01 per share on revenue of $1.55 billion. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $532.04 million. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $533.26 million. 
• Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $417.67 million. 
• DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $85.54 million. 
• Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $65.48 million. 
• OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $128.13 million. 
• MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $726.90 million. 
• Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $245.02 million. 
• Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $181.92 million. 
• Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is projected to report quarterly earnings at $1.12 per share on revenue of $2.12 billion. 
• Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $80.90 million. 
• Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) is projected to report quarterly earnings at $0.53 per share on revenue of $209.12 million. 
• Gladstone Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLAD#NASDAQ">GLAD</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $24.40 million. 
• InvenTrust Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVT#NYSE">IVT</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $71.16 million. 
• Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $254.21 million. 
• Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $21.43 million. 
• Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $491.36 million. 
• Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) is likely to report quarterly earnings at $3.51 per share on revenue of $3.08 billion. 
• Acadia Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKR#NYSE">AKR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $83.33 million. 
• Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) is estimated to report quarterly earnings at $4.58 per share on revenue of $2.22 billion. 
• Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) is projected to report quarterly earnings at $0.86 per share on revenue of $203.87 million. 
• Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $189.30 million. 
• DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $2.84 billion. 
• Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) is projected to report quarterly earnings at $1.03 per share on revenue of $156.13 million. 
• Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $256.84 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALSN

ANGI

ARVN

ATEX

ATOM

Brighthouse Financial, Inc. - Common Stock

BIOX

CARR

CFLT

CRNT

CURB

DASH

DIOD

ELMD

EXEL

FORR

FRSH

GILD

GLAD

GNSS

HIVE

IPGP

JRSH

LCII

LDOS

LYFT

MCRI

MYTE

OESX

RPRX

SAGE

SHOP

SMCI

SMWB

SPGI

SQNS

TYGO

UFCS

UPST

USAC

WELL

YTRA

Earnings Scheduled For February 11, 2025

Goldman Sachs analyst Salveen Richter maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Neutral and raises the price target from $5.5 to $7.5.

Goldman Sachs Maintains Neutral on Adaptive Biotechnologies, Raises Price Target to $7.5

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), a leading oncology testing services company, today announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease (MRD) monitoring options for patients with select blood cancers.

Adaptive Biotechnologies and NeoGenomics Partner to Enhance MRD Monitoring for Blood Cancer Patients

On Monday, Cathie Wood-led Ark Invest made significant trades in five major companies: Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), CareDx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The PLTR Trade
Ark Invest&#8217;s Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) fund sold 140,518 shares of Palantir. This move is significant, considering Ark Invest&#8217;s&nbsp;<a href="https://www.benzinga.com/25/01/42865484/cathie-woods-tuesday-double-dump-ark-invest-trims-both-palantir-and-bitcoin-etf-holdings">recent trend of offloading Palantir shares</a>.
The total value of this trade, based on the latest closing price of $64.98, is approximately $9.1 million.
This sale follows Ark&#8217;s disposal of shares worth roughly $15 million the previous week.
Palantir stock price has fallen more than 14% over the past month. In just the first two weeks of 2025, the stock has declined nearly 15%.
The TEM Trade
Ark Invest&#8217;s ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARKK funds made substantial purchases of Tempus AI Inc. shares. The ARKG fund bought 98,691 shares, while the ARKK fund purchased a whopping 280,192 shares.
Given the latest closing price of $32.34, the total value of these trades amounts to approximately $12.2 million.
This move comes amid TEM&#8217;s 13.81% drop on Monday.
Other Key Trades:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>ETF</td>
<td>Transaction</td>
<td>No. Of Shares</td>
<td>Closing price</td>
<td>Approx. Value</td>
</tr>
<tr>
<td>Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>37,358</td>
<td>$42.78</td>
<td>$1.6 million</td>
</tr>
<tr>
<td>Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>76,522</td>
<td>$6.46</td>
<td>$494,332</td>
</tr>
<tr>
<td>CareDx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>65,550</td>
<td>$25.07</td>
<td>$1.6 million</td>
</tr>
</tbody>
</table>
</figure>
Closing price as of Jan. 13, 2025
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-post-joe-rogan-appearance">Mark Zuckerberg Critiques &#8216;Culturally Neutered&#8217; Companies, Advocates For &#8216;Masculine Energy&#8217; As Meta Cuts DEI Programs Post-Joe Rogan Appearance</a></li>
</ul>
Image via Benzinga YouTube and Unsplash
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/Rounak-Jain" target="_blank" rel="noreferrer noopener">Rounak Jain</a>

Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025

Cathie Wood-led&nbsp;Ark Invest&nbsp;made significant trades in five major companies on Friday: Recursion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Intellia Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), Cloudflare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), and Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The RXRX Trade
Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) purchased a substantial 264,596 shares of&nbsp;Recursion Pharmaceuticals.
The value of this trade, calculated from the closing price of $6.88, is approximately $1.82 million. This move comes despite RXRX&#8217;s stock closing at a 5.23% decrease on Friday.
The ILMN Trade
Ark Invest&#8217;s Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARK Innovation ETF both bought shares of&nbsp;Illumina Inc.
ARKG acquired 4038 shares, while ARKK purchased 11425 shares. The combined value of these trades, calculated from the closing price of $136.69, is approximately $1.97 million.
This move was made despite Illumina's stock closing at a 2.14% decrease on Friday.
See Also: <a href="https://www.benzinga.com/25/01/42931747/bitcoin-supercycle-incoming-says-economist-but-theres-a-catch">Bitcoin Supercycle Incoming, Says Economist, But There&#8217;s A Catch</a>
The NTLA Trade
Ark Invest&#8217;s Genomic Revolution ETF and ARK Innovation ETF both bought shares of&nbsp;Intellia Therapeutics.
ARKG acquired 41503 shares, while ARKK purchased 124799 shares.
The combined value of these trades, calculated from the closing price of $10.2, is approximately $1.46 million. This move was made despite NTLA&#8217;s stock closing at a 15.14% decrease on Friday.
Intellia Therapeutics announced a 27% workforce reduction on Friday to cut costs.
The NET Trade
Ark Invest&#8217;s Next Generation Internet ETF (ARKW) sold 7840 shares of&nbsp;Cloudflare.
The value of this trade, calculated from the closing price of $112.62, is approximately $882,608. This move was made despite NET&#8217;s stock closing at a 2.66% decrease on Friday.
The ADPT Trade
Ark Invest&#8217;s Genomic Revolution ETF sold 130,790 shares of&nbsp;Adaptive Biotechnologies.
The value of this trade, calculated from the closing price of $6.5, is approximately $850,135. This move was made despite ADPT&#8217;s stock closing at a 2.84% decrease on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-">Mark Zuckerberg Critiques &#8216;Culturally Neutered&#8217; Companies, Advocates For &#8216;Masculine Energy&#8217; As Meta Cuts DEI Programs Post-Joe Rogan Appearance</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Ark Invest

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Buy and raises the price target from $8 to $9.

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $9

As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</h3>
<ul>
<li>On Dec. 7, Adaptive Biotechnologies presented new data at ASH 2024 showcasing clonoSEQ MRD testing advances and its role in guiding blood cancer treatment decisions. The company's shares gained around 6% over the past month and has a <a href="https://www.benzinga.com/quote/ADPT">52-week high of $7.07</a>.</li>
<li>RSI Value: 75.83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ADPT Price Action: Shares of Adaptive Biotechnologies gained 4.2% to close at $6.71 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">NewAmsterdam Pharma Company NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>)</h3>
<ul>
<li>On Dec. 10, NewAmsterdam Pharma revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The company's stock gained around 30% over the past five days and <a href="https://www.benzinga.com/quote/NAMS">has a 52-week high</a> of $26.36.</li>
<li>RSI Value: 81.17</li>
<li>NAMS Price Action: Shares of NewAmsterdam Pharma jumped 41.4% to close at $26.19 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Paragon 28 Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNA#NYSE">FNA</a>)</h3>
<ul>
<li>On Nov. 12, Paragon 28 reported quarterly losses of 15 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $62.30 million which beat the analyst consensus estimate of $60.58 million. The company's stock gained around 38% over the past month and has a <a href="https://www.benzinga.com/quote/FNA">52-week high</a> of $14.79.</li>
<li>RSI Value: 77.07</li>
<li>FNA Price Action: Shares of Paragon 28 gained 5% to close at $10.50 on Tuesday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42429201/dow-falls-for-4th-straight-session-alphabet-surges-on-google-quantum-chip-announcement-fear-greed-index-remains-in-neutral-zone">Dow Falls For 4th Straight Session, Alphabet Surges On Google Quantum Chip Announcement: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Trading Ideas

NAMS

Top 3 Health Care Stocks That May Collapse This Quarter

<ul>
<li>New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL</li>
<li>Studies show depth of response at 10-6 provides more accurate assessment of treatment responses</li>
</ul>

Reported Saturday, Adaptive Biotechnologies Presented New Data at ASH 2024 Showcasing clonoSEQ MRD Testing Advances And Its Role In Guiding Blood Cancer Treatment Decisions

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
What Happened: Wood&#8217;s enthusiasm centers on what she describes as a transformative convergence of technologies that could revolutionize medical treatment and drug discovery. 
Speaking candidly about the sector, Wood highlighted the remarkable progress in genetic therapies, particularly in companies like Crispr Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), and Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>).
Her most striking example involves Crispr Therapeutics&#8217; recent breakthrough in sickle cell disease treatment. Wood noted, referencing how patients who previously required 12 to 20 annual blood transfusions might now be free from such interventions.
The strategy extends beyond treatment breakthroughs to drug development itself. Wood points to companies like Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) as leveraging artificial intelligence to dramatically reduce clinical trial failure rates and accelerate drug development timelines.
However, the market performance of these innovative companies tells a more nuanced story. Year-to-date, the stocks have experienced significant volatility: Crispr Therapeutics is down 25.36%, Intellia Therapeutics has dropped 52.21%, Beam Therapeutics declined 3.04%, and Recursion Pharmaceuticals fell 9.80%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space. Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/entertainment/24/11/42205763/disney-reaches-43m-settlement-in-gender-pay-discrimination-lawsuit-women-can-expect-equitable-treatment-moving-forward">Disney Reaches $43M Settlement In Gender Pay Discrimination Lawsuit: &#8216;Women Can Expect Equitable Treatment&#8217; Moving Forward</a>
Why It Matters: ARK&#8217;s commitment to this sector is evident through its Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>), which manages net assets of $1.179 billion. The fund&#8217;s performance reflects the sector&#8217;s volatility, with annual returns ranging from a high of 180.50% in 2020 to a low of -53.94% in 2022.
The ETF&#8217;s current top holdings underscore Wood&#8217;s strategic focus on innovative biological technologies. Twist Bioscience Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) leads the portfolio at 8.90%, followed by Crispr Therapeutics at 7.88% and Recursion Pharmaceuticals at 6.17%. Other significant investments include CareDx Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), and Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), representing a diversified approach to genomic and biological innovation.
Wood&#8217;s vision suggests a potential $400 billion market opportunity in biologics over the next five years, driven by the unprecedented convergence of AI, sequencing technologies, and gene editing. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42202496/goldman-sachs-expects-major-selloffs-in-canadian-dollar-mexican-peso-says-trump-tariffs-threaten-usmca-agreement">Goldman Sachs Expects Major Selloffs In Canadian Dollar, Mexican Peso, Says Trump Tariffs Threaten USMCA Agreement</a></li>
</ul>
Image via Ark Invest
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Biotech

Health Care

CRSP

TWST

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Adaptive Biotechnologies shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $6 to $7.

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Overweight and raises the price target from $6 to $7.

Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $7

Adaptive Biotechnologies shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.29) by 24.14 percent. The company reported quarterly sales of $46.435 million which beat the analyst consensus estimate of $40.208 million by 15.49 percent. This is a 22.46 percent increase over sales of $37.919 million the same period last year.

Adaptive Biotechnologies Q3 2024 GAAP EPS $(0.22) Beats $(0.29) Estimate, Sales $46.435M Beat $40.208M Estimate

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) raises FY2024 sales outlook from $140.00 million-145.00 million to $143.00 million-145.00 million.

Adaptive Biotechnologies Raises FY2024 Sales Guidance from $140.00M-145.00M to $143.00M-145.00M

Press Releases

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

General

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Small Cap

Opinion

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

ELEV

ONCY

ORIC

TSX:ONC

Agilent Technologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. Class B Common Stock

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Piper Sandler

Scotiabank

Goldman Sachs

BTIG

JP Morgan

금요일에 캐시 우드가 이끄는 안크 인베스트가 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), 누 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>), 메르카도리브레(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), 그리고 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)와 관련하여 큰 거래를 했다.
BEAM 거래
아크 인베스트는 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)와 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 빔 테라퓨틱스의 주식 24,640주를 매입했다.
이는 해당 회사가 일주일 전 <a href="https://www.benzinga.com/25/02/43755344/cathie-woods-ark-invest-loads-up-on-iridium-twist-bioscience-offloads-roku-here-are-key-ark-trades-this-friday">빔 테라퓨틱스 주식</a>을 이전에 매수한 후 이루어진 것이다. 이 거래의 가치는 최신 종가를 기준으로 약 75만 달러에 달한다.
NU 거래
아크 인베스트는 ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)를 통해 누 홀딩스의 주식 162,143주를 매입했다. 이는 이 핀테크 회사에 대한 상당한 투자로, 아크의 역동적인 기술 부문에서의 전략적 포지셔닝을 반영한다.
이 거래의 가치는 최신 종가를 기준으로 175만 달러를 초과한다.
MELI와 ADPT 거래
같은 날, 아크 인베스트는 또한 메르카도리브레와 어댑티브 바이오테크놀로지스의 주식을 매도했다. ARK Fintech Innovation ETF를 통해 아크는 메르카도리브레 주식 347주를 매각했다.
한편, ARK Genomic Revolution ETF를 통해 아크는 어댑티브 바이오테크놀로지스 주식 8,129주를 매각했다.
다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/25/02/43900360/bill-gates-has-a-warning-for-the-next-generation-says-be-very-afraid-of-these-4-issues">빌 게이츠가 다음 세대에 경고합니다. 매우 두려워해야 할 4가지 문제를 말합니다.</a></li>
</ul>
면책 조항: 이 콘텐츠는 AI 도구의 도움으로 부분적으로 생성되었으며, Benzinga 편집자에 의해 검토되고 발표되었습니다.
사진 출처: Ark Invest
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

월요일(13일) 캐시 우드가 이끄는 아크 인베스트는 팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), 템퍼스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) 등 5개의 주요 기업에서 중요한 거래를 진행했다.
<h3>팔란티어 거래</h3>
아크 인베스트의 Ark Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)는 팔란티어 주식 140,518주를 매각했다. 이는 아크 인베스트가 최근에 팔란티어 주식을 처분하는 추세를 보인 것을 감안할 때 중요한 움직임이며, <a href="https://www.benzinga.com/25/01/42865484/cathie-woods-tuesday-double-dump-ark-invest-trims-both-palantir-and-bitcoin-etf-holdings">최근 경향</a>을 고려할 때 주목할 만하다.
최근 종가인 64.98달러를 기준으로 한 이번 거래의 총 가치는 약 910만 달러에 달한다. 이번 매각은 지난주 아크 인베스트가 약 1,500만 달러 상당의 팔란티어 주식을 처분한 데 이어 나타났다.
팔란티어 주가는 지난 한 달 동안 14.22% 하락했고, 올해 들어서는 14.77% 하락했다.
<h3>템퍼스 AI 거래</h3>
아크 인베스트의 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)와 ARKK 펀드는 템퍼스 AI 주식 상당량을 매입했다. ARKG 펀드는 98,691주를 매입했고 ARKK 펀드는 무려 280,192주를 매입했다.
최근 종가인 32.34달러를 감안할 때, 이번 매입 거래의 총 가치는 약 1,220만 달러에 달한다. 이러한 움직임은 월요일에 템퍼스 AI 주가가 13.81% 하락한 가운데 나온 것이다.
<h3>기타 주요 거래</h3>
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>회사</td>
<td>ETF</td>
<td>거래</td>
<td>주식 수</td>
<td>종가</td>
<td>대략적 가치</td>
</tr>
<tr>
<td>베라사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>매도</td>
<td>37,358</td>
<td>$42.78</td>
<td>$160만</td>
</tr>
<tr>
<td>어댑티브 바이오테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>매도</td>
<td>76,522</td>
<td>$6.46</td>
<td>$494,332</td>
</tr>
<tr>
<td>케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>)</td>
<td>ARK Genomic Revolution</td>
<td>매도</td>
<td>65,550</td>
<td>$25.07</td>
<td>$160만</td>
</tr>
</tbody>
</table>
</figure>
2025년 1월 13일 기준 종가
이미지 제공: Benzinga YouTube 및 Unsplash
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며 <a href="https://www.benzinga.com/author/Rounak-Jain" target="_blank" rel="noreferrer noopener">Rounak Jain</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

캐시 우드가 이끄는 아크 인베스트는 금요일에 리커젼 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), 클라우드플레어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) 그리고 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)의 주요 회사들에서 상당한 거래를 진행했다.
<div class="ticker-wrapper">
<div class="sc-icgYrN gsJcQM ticker-box-wrapper">
<div class="sc-hZlppA ddOBfh get-report-button flex">
<div></div>
</div>
</div>
</div>
RXRX 거래
아크 인베스트(Ark Invest)의 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)가 리커젼 파마슈티컬스의 주식 264,596주를 대량으로 매수했다.
이 거래의 가치는 종가인 6.88달러를 기준으로 약 1.82 백만 달러이다. 이 결정은 금요일에 RXRX의 주가가 5.23% 하락한 것에도 불구하고 이루어졌다.
ILMN 거래
아크 인베스트의 Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)와 ARK Innovation ETF가 일루미나의 주식을 매수했다.
ARKG는 4,038주를 매수했고, ARKK는 11,425주를 매수했다. 이 거래들의 총 가치는 종가인 136.69달러를 기준으로 약 1.97 백만 달러이다.
이 결정은 일루미나의 주가가 금요일에 2.14% 하락한 것에도 불구하고 이루어졌다.
참고: <a href="https://www.benzinga.com/25/01/42931747/bitcoin-supercycle-incoming-says-economist-but-theres-a-catch">비트코인 슈퍼사이클이 온다, 경제학자가 말하지만, 함정이 있다</a>
NTLA 거래
아크 인베스트의 Genomic Revolution ETF와 ARK Innovation ETF가 인텔리아 테라퓨틱스의 주식을 매수했다.
ARKG는 41,503주를 매수했고, ARKK는 124,799주를 매수했다.
이 거래들의 총 가치는 종가인 10.2달러를 기준으로 약 1.46 백만 달러이다. 이 결정은 NTLA의 주가가 금요일에 15.14% 하락한 것에도 불구하고 이루어졌다.
인텔리아 테라퓨틱스는 금요일에 비용 절감을 위해 27%의 인력 감축을 발표했다.
NET 거래
아크 인베스트의 Next Generation Internet ETF(ARKW)가 클라우드플레어의 주식 7,840주를 매도했다.
이 거래의 가치는 종가인 112.62달러를 기준으로 약 882,608달러이다. 이 결정은 NET의 주가가 금요일에 2.66% 하락한 것에도 불구하고 이루어졌다.
ADPT 거래
아크 인베스트의 Genomic Revolution ETF가 어댑티브 바이오테크놀로지스의 주식 130,790주를 매도했다.
이 거래의 가치는 종가인 6.5달러를 기준으로 약 850,135달러이다. 이 결정은 ADPT의 주가가 금요일에 2.84% 하락한 것에도 불구하고 이루어졌다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-">마크 저커버그가 &#8216;문화적으로 무력화된&#8217; 기업들을 비판하고, 메타가 DEI 프로그램을 중단하자 &#8216;남성 에너지&#8217;를 옹호하다</a></li>
</ul>
면책조항: 이 콘텐츠는 AI 도구의 도움으로 부분적으로 생성되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
사진 제공: Ark Invest


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.
무슨 일 있었나: 캐시 우드의 열정은 의료와 신약 개발에 혁명을 일으킬 수 있는 혁신적인 기술 융합에 집중되어 있다.
그는 이 분야에 대해 솔직하게 이야기하면서 특히 크리스퍼 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) 같은 회사에서 유전자 치료의 괄목할 만한 발전이 이루어지고 있다고 강조했다.
가장 눈에 띄는 사례는 최근 크리스퍼 테라퓨틱스가 겸상 적혈구 질환 치료 분야에서 거둔 획기적인 성과다. 우드는 이전에는 연간 12~20회 수혈을 받아야 했던 환자들이 이제 그런 수혈을 받지 않아도 될 수 있게 되었다고 언급했다.
이러한 전략은 치료의 혁신을 넘어 신약 개발 자체로 확장횐다. 우드는 리커션 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>)와 같은 회사가 인공지능을 활용하여 임상시험 실패율을 획기적으로 줄이고 신약 개발 일정을 앞당기고 있다고 강조했다.
그러나 이러한 혁신적인 기업들의 시장 성과는 좀 더 복잡한 이야기를 담고 있다. 올해 들어 이들 주식은 상당한 변동성을 보였다. <a href="//www.benzinga.com/pro/"" target="_blank" rel="noopener">벤징가 프로 데이터</a>에 따르면 연초 대비 크리스퍼 테라퓨틱스는 25.36% 하락, 인텔리아 테라퓨틱스는 52.21% 하락, 빔 테라퓨틱스는 3.04% 하락, 리커션 제약은 9.80% 하락했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space.
Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C%EC%9D%98-%EC%95%84%ED%81%AC-%EC%9D%B8%EB%B2%A0%EC%8A%A4%ED%8A%B8-%ED%85%8C%EC%8A%AC%EB%9D%BC-%EC%A3%BC%EC%8B%9D-1800%EB%A7%8C-%EB%8B%AC%EB%9F%AC-%EC%83%81/" target="_blank" rel="noopener">캐시 우드의 아크 인베스트, 테슬라 주식 1,800만 달러 상당 매각</a>
왜 중요한가: 바이오 분야에 대한 아크 인베스트의 노력은 11억 7,900만 달러의 순자산을 관리하는 Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)를 통해 분명하게 드러난다. 이 펀드의 성과는 2020년 최고 180.50%에서 2022년 최저 -53.94%에 이르는 연간 수익률로 해당 섹터의 변동성을 반영하고 있다.
이 ETF의 현재 상위 보유 종목은 혁신적인 바이오 기술에 대한 캐시 우드의 전략적 초점을 강조한다. 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>)가 8.90%의 비중으로 포트폴리오를 이끌고 있으며, 크리스퍼 테라퓨틱스가 7.88%, 리커션 파마슈티컬스가 6.17%로 그 뒤를 잇고 있다. 그 밖의 주요 투자 기업으로는 케어DX(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) 등이 있으며, 이들은 게놈 및 생물학적 혁신에 대한 다양한 접근 방식을 대표한다.
캐시 우드는 AI, 시퀀싱 기술, 유전자 편집의 전례 없는 융합 덕분에 향후 5년 동안 바이오 분야에서 4,000억 달러의 시장 기회가 있을 것으로 전망한다.
이미지 출처: Ark Invest
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토 후 게시했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

캐시 우드, 바이오 분야에서 4천억 달러 기회 전망

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob" target="_blank" rel="noopener" data-google-interstitial="false">혁신 분야</a>에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다.
이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.
아크 이노베이션: 우드와 <a href="https://www.benzinga.com/topic/ark-funds">아크 펀드</a>는 Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 2014년 10월 31일에 출시했다. 이 펀드는 이 회사의 가장 유명하고 가장 큰 펀드로 성장했으며, 현재 57억 8천만 달러의 운용 자산을 보유하고 있다.
&#8220;ARRK는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 국내 및 해외 주식에 주로 투자하여 펀드의 투자 테마인 파괴적 혁신(disruptive innovation)와 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkk">웹사이트</a>에서 설명한다.
파괴적 혁신 테마에는 자율 이동성, 정밀 치료, 차세대 클라우드, 신경망, 지능형 기기, 디지털 지갑, 디지털 자산, 스마트 계약 및 멀티오믹 기술이 포함된다.
&#8220;ARK는 &#8216;파괴적 혁신&#8217;을 세상이 돌아가는 방식에 잠재적으로 도전할 수 있는 기술적으로 구현된 새로운 제품이나 서비스의 도입으로 정의한다.&#8221;
현재 ARKK ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 14.1%</li>
<li>로쿠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 10.8%</li>
<li>코인베이스 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 8.1%</li>
<li>로블록스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>): 6.2%</li>
<li>팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 5.1%</li>
<li>로빈후드 마켓 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 5.0%</li>
<li>블록 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>): 4.9%</li>
<li>크리스퍼 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): 4.5%</li>
<li>쇼피파이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 3.9%</li>
<li>유아이패스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): 2.9%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 161.4% 상승했다. 이 수익률은 S&amp;P 500을 추적하는 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)의 현재 10년 수익률에는 미치지 못한다.
아래의 표는 ARKK의 수익률이 SPY와 어떻게 비교되는지를 보여준다. SPY는 <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41407647/spy-reaches-600-billion-in-assets-oldest-us-ETF-hits-milestone-as-all-time-highs-conti">가장 오래되고 가장 큰</a> 미국 ETF이다:
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKK</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>+19.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-24.3%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>+2.6%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKK 설립 이래 2014년 10월 31일 기준</td>
<td>+10.2%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
아래의 차트는 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro</a>에서 제공한 ARKK의 10년 수익률을 보여준다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png" sizes="(max-width: 1003px) 100vw, 1003px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png 1003w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-768x393.png 768w" alt="" width="1003" height="513" /></a></figure>
비교를 위해 SPY의 10년 차트도 보여드리겠다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png" sizes="(max-width: 995px) 100vw, 995px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-768x392.png 768w" alt="" width="995" height="508" /></a></figure>
다음 읽어보기: <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">독점: 캐시 우드가 테슬라가 기술 주식으로 거래되어야 하는 이유를 Benzinga에 말했다.</a>
아크 지노믹스: Ark Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)는 2014년 10월 31일에 아크 펀드에 의해 출시되었다. 현재 이 ETF 펀드는 13억 3천만 달러의 자산을 운용하고 있다.
&#8220;ARKG는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 헬스 케어, 정보 기술, 소재, 에너지 및 소비재 등 여러 섹터의 국내외 주식에 주로 투자하며, 펀드의 투자 테마인 유전체 혁명(genomics revolution)과 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkg">웹사이트</a>에서 설명한다.
이 유전체 혁명 ETF의 테마에는 정밀 치료, 멀티오믹 기술, 프로그래머블 생물학, 신경망, 차세대 클라우드 및 적응형 로보틱스가 포함된다.
현재 ARKG ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>트위스트 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): 8.7%</li>
<li>리커젼 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>): 7.0%</li>
<li>크리스퍼 테라퓨틱스: 7.0%</li>
<li>케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>): 5.1%</li>
<li>어댑티브 바이오테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>): 4.7%</li>
<li>베라사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYCT#NASDAQ">VYCT</a>): 4.6%</li>
<li>아이오니스 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>): 4.3%</li>
<li>누릭스 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>): 4.1%</li>
<li>나테라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 3.8%</li>
<li>10x 지노믹스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): 3.8%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 38.9% 상승했다. 이 수익률은 현재 SPDR S&amp;P 500 ETF Trust의 10년 수익률에는 미치지 못한다.
ARKG의 수익률이 SPY와 어떻게 비교되는지를 살펴보겠다.
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKG</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>-7.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-29.9%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>-1.9%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKG 설립 이래 2014년 10월 31일 기준</td>
<td>+3.3%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
다음은 ARKG의 10년 차트다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624525" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png" sizes="(max-width: 993px) 100vw, 993px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-768x394.png 768w" alt="" width="993" height="510" /></a></figure>
중요성 (Why It&#8217;s Important): 위의 차트들은 ARKK와 ARKG가 모두 투자자들에게 몇 년 동안 강력한 성장과 수익률을 경험했지만, 최근 몇 년 동안은 더 넓은 S&amp;P 500 시장 지수를 하회한 것을 보여준다.
한때 이 ETF들은 가장 화제가 된 펀드들 중 하나였으며, 이 회사의 일일 거래 활동은 종종 주식을 상승시켰다. 이는 우드의 뛰어난 성과 덕분이다.
S&amp;P 500 ETF는 분기마다 리밸런싱을 하지만, 이 액티브하게 관리되는 펀드는 거의 매일 거래를 완료한다. 종종 주가가 상승하는 주식의 평균 매입가가 시간이 지남에 따라 상승하여 수익률에 부정적인 영향을 미칠 수 있다.
아크 펀드는 일반적으로 향후 5년에서 10년 동안 강력한 성장을 할 것으로 믿는 회사들에 투자한다. 이는 펀드의 수익률이 때때로 몇 년이 걸려야 나타날 수 있음을 의미한다.
우드는 엔비디아의 주식을 2014년에 약 5달러에 매수한 것과 같이 많은 테마에 대해 일찍 투자한 바 있다. 이는 가장 최근의 주식 분할 이전의 일이었다. 이 펀드는 나중에 2022년 말과 2023년 초에 이 포지션에서 완전히 매도하여 지난 2년 가까이 <a style="font-size: revert;" href="https://www.benzinga.com/general/education/24/02/37294405/heres-how-much-cathie-wood-ark-invest-flagship-fund-missed-by-selling-nvidia-early">엄청난 수익을 놓쳤</a>다.
이 펀드 매니저는 또한 테슬라 성장 스토리에 일찍 투자했다. 2018년 2월에 이 전기차 회사에 대해 $4,000 목표 주가를 <a href="https://www.benzinga.com/news/22/03/26046331/if-you-invested-1-000-in-tesla-when-cathie-wood-made-her-4-000-prediction-heres-how-much-youd-have-n-1" target="_blank" rel="noopener">예측</a>했다. 당시에는 가격 예측으로 비웃음거리가 되었지만, 주가는 2021년 1월에 분할 기준으로 목표 주가에 도달했다.
테슬라에 대한 예측이 맞아들어간 것은 우드의 펀드 매니저로서의 위상을 높이는 데 도움이 되었고, 아크 펀드 ETF들에 대한 관심이 증가하는 계기가 되었다.
최근 몇 년 동안 아크 펀드 ETF들에 대한 관심이 식었지만, 많은 투자자들은 여전히 그들의 영향을 기억하고 일일 거래 활동을 계속 추적하며, 우드가 향후 5년에서 10년 동안 보유할 주식을 주의 깊게 지켜보고 있다.

다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">독점: 캐시 우드는 왜 비트코인이 100만 달러에 이를 것이라고 생각하는가? 그녀는 무엇을 알고 있기에?</a></li>
</ul>
이미지 제공: Ark Invest 및 Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Broad U.S. Equity ETFs

Education

Specialty ETFs

COIN

HOOD

IONS

NRIX

NTRA

PATH

RBLX

ROKU

TSLA

VYCT

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&P 500과 비교

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)에 주목할 만한 투자를 했다. 이는 인공 지능(AI) 부문이 탄력을 받으면서 이루어진 움직임이다.
팔란티어(PLTR) 거래
아크 인베스트는 ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)를 통해 팔란티어의 주식 199,372주를 매입했는데, 이는 포트폴리오에 상당한 추가 금액이다. 이번 거래 가치는 당일 종가 25.88달러를 기준으로 약 516만 달러에 이른다.
팔란티어는 최근 모멘텀 투자자들로부터 &#8216;AI 헤일로(AI Halo)&#8217; 플레이로 칭찬을 받았다. 이 회사는 3분기 BofA 증권의 미국 최고의 아이디어 10개 목록에 추가되어 AI 부문에서 점점 더 <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39582335/momentum-investor-praises-palantir-as-ai-halo-play-highlights-datadog-as-software-bottom">인기</a>를 얻고 있음을 강조했다. 버투스 인베스트먼트 파트너스(Virtus Investment Partners)의 조 테라노바(Joe Terranova)는 팔란티어가 AI 후광에 적극적으로 참여하는 AI 공간의 핵심 플레이어라고 설명했다.
팔란티어의 공동 창립자 피터 틸(Peter Thiel)은 최근 아스펜 아이디어 페스티벌(Aspen Ideas Festival)에서 AI 환경에 대한 <a href="https://www.benzinga.com/news/24/07/39569675/palantirs-peter-thiel-says-its-very-strange-that-most-money-in-ai-is-being-made-by-only-one-company" target="_blank" rel="noopener">통찰력</a>을 공유하면서 닷컴 버블과 AI의 현재 상태 사이의 유사점을 그렸다.
그 외의 중요한 거래:
<ul>
<li>아크 인베스트의 ARKG가 어댑티브 바이오 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)의 주식을 매수했다.</li>
<li>ARKK는 리커전 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) 주식을 구매했다. ARKQ도 블레이드 에어 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>)의 주식도 포트폴리오에 추가했다.</li>
<li>ARKF는 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 팔았다.</li>
</ul>
이 이야기는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 통해 제공되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었다.

ARKQ

BLDE

캐시 우드의 아크 인베스트는 AI 열풍 속에서 516만 달러 가치의 팔란티어 주식 매수

Comments

Adaptive Biotechnologies

뉴스

에 대한 최신 뉴스 Adaptive Biotechnologies (NASDAQ:ADPT) 주식

일요일, 2월 23, 2025

화요일, 1월 14, 2025

일요일, 1월 12, 2025

수요일, 11월 27, 2024

금요일, 11월 01, 2024

화요일, 7월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌